Colorado Black Resource Directory connects patients with specialized health care
"It's all encompassing," said Dr. Terri Richardson, co-founder of CBHR. "We go cradle to grave, that's what we say." Recently, she gathered with a group of fellow Black women to celebrate the release of CBHR. Richardson says the idea first came about in 2010, a response to requests for information from Black Coloradans seeking to connect with medical providers who understand their unique concerns. It's now in its fifth edition.
"People said, 'You know what we could use? A holistic view of health.' A guide. We wanted to cover the Black diaspora not just African Americans. Folks from all over," she told CBS News Colorado's Mekialaya White. According to the state of Colorado, in 2023, 4.18% of our population was Black or African American alone. It's a population that needs these resources, Richardson says.
"Sometimes, we feel like we get lost here in Colorado being only a small percentage of the population, yet our health disparities are at the top or the bottom as we always say."
Lielt Bedilu knows the struggle all too well. She says finding her current pediatrician, Dr. Sophia Meharena was an answered prayer. "There are things walking around as a Black individual that every day that you have to explain. You have to explain things about your culture, the way you speak, all these nuances, like your hair. I think the physician-patient relationship is so sacred, intimate, and vulnerable and my hope would be that we wouldn't have to do that in that space," she said. "It's not about being a better physician," explained Meharena. "It's about being able to connect with your patient in a way that the patient is looking for." But doctor by doctor, the directory works to make offices more welcoming. "It's very important to have someone with that lived experience. You don't have to explain to me what it means to be Black in America. I already know," added Richardson.
President Trump wants to dismantle the Department of Education. Here's what would be impacted.
Doctor calls Trump's vaccine order "theater" because no schools have COVID vaccine mandates
Saturday Sessions: Aloe Blacc performs "One Good Thing"
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
22 minutes ago
- Newsweek
Top Scientist Issues Stark mRNA Vaccine Warning to U.S.
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Rick Bright, the former director of the Biomedical Advanced Research and Development Authority (BARDA) has warned that Department of Health and Human Services' decision to cut funding for mRNA vaccine development could threaten American national security. "BARDA wasn't the only government agency making early investments in mRNA research," Bright wrote in an opinion piece for The New York Times. "The Department of Defense and the Defense Advanced Research Projects Agency had already recognized mRNA's potential for swift action against emerging biological threats, including those that might be weaponized." It comes after HHS Secretary Robert F. Kennedy Jr. announced the termination of 22 mRNA development investments and the reallocation of roughly $500 million at the beginning of this month. Why it Matters Bright said the mRNA platform had been central to the fast response to COVID-19 and that abandoning the technology would undermine the nation's ability to respond quickly to future biological threats. Multiple scientists and doctors have spoken out against this decision, including infectious diseases expert Dr. Thomas A. Russo, who told Newsweek that mRNA vaccines "will be critical when the next, inevitable infectious diseases crisis rears its ugly head." What To Know On August 5, the HHS confirmed it would cancel $500 million in mRNA vaccine development contracts, impacting research teams and proposals—including those from Emory University, Tiba Biotech, Pfizer, Sanofi Pasteur and others. The projects reportedly targeted respiratory viruses including seasonal influenza, COVID-19, RSV and H5N1 and included work by major industry and academic teams. Secretary Kennedy argued that the data showed mRNA vaccines had not met expectations for preventing upper respiratory infections and that HHS would shift funding toward other vaccine platforms. But Bright praised mRNA technology, saying that the "unprecedented speed" with which a COVID-19 vaccine was developed in 2020 "was possible only because years earlier, the United States had invested" in it. "This decision undercuts one of the most significant medical advances in decades, technology that could protect millions more people from the threats ahead," Bright said. "I know the stakes because I was BARDA's director when the United States made the decision to invest heavily in mRNA," he said. "That investment did not begin with Covid-19. It began in 2016, when we faced the Zika virus outbreak." "We needed a way to design a vaccine in days, not years, to protect pregnant women and their babies from devastating birth defects. Older vaccine approaches were too slow," Bright continued. "The solution was mRNA: a flexible, rapid-response technology that could be reprogrammed for any virus once its genetic sequence was known. That early investment laid the groundwork for the lightning-fast Covid-19 response four years later." Kennedy said in a post on X the time: "We reviewed the science, listened to the experts, and acted. BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu," Kennedy said in a post on X. "We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate." Newsweek has contacted the HHS, via online inquiry form, for a response to Bright's comments. File photo of an employee of the Bavarian Red Cross (BRK) preparing the BioNTech/Pfizer vaccine against the coronavirus SARS-CoV-2 for vaccination in a vaccination center, taken in Bavaria, Germany, in January 2021. File photo of an employee of the Bavarian Red Cross (BRK) preparing the BioNTech/Pfizer vaccine against the coronavirus SARS-CoV-2 for vaccination in a vaccination center, taken in Bavaria, Germany, in January 2021. AP What People Are Saying Former BARDA director Rick Bright said in his NYT op-ed: "Like every technology, mRNA has limitations. Vaccines meant to protect against respiratory infections, whether developed through mRNA or older technologies, are generally better at averting severe disease than preventing infection. It is a scientific challenge we can address with next-generation vaccines. The answer to limitations is improvement, not abandonment. "Political narratives about mRNA have fueled confusion, which leads to mistrust, yet the scientific evidence consistently shows that this technology is safe and effective and holds enormous potential for future vaccines and treatments." Children's Health Defense, an anti-vax nonprofit founded by Kennedy Jr. which focuses on childhood health epidemics, said in a post on X: "CHD applauds this most recent announcement to defund 22 mRNA vaccine projects under BARDA. While we believe that the mRNA shots on the market are unsafe and should be off the market, this is a welcome step in the right direction. The pandemic preparedness industry as it exists today is a threat to human welfare." What Happens Next HHS said it would shift funding toward other vaccine platforms but did not provide detailed timelines or specify which programs would receive redirected support. Scientific organizations, industry groups and public-health leaders said they would assess the impact and consider next steps, while some public-health advocates announced initiatives to defend vaccine science and provide public information.
Yahoo
23 minutes ago
- Yahoo
Warren Buffett's Berkshire Hathaway Buys Over 5 Million Shares in UnitedHealth Group (UNH)
UnitedHealth Group Incorporated (NYSE:UNH) is one of the most buzzing stocks to invest in right now. CNBC reported on August 14 that Warren Buffett's Berkshire Hathaway bought more than 5 million shares in UnitedHealth Group Incorporated (NYSE:UNH) last quarter, coming up to a stake worth around $1.6 billion. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated's (NYSE:UNH) shares soared after Buffett's latest quarterly filing was revealed, marking a 'surprising buy' due to the healthcare company's present reputation. According to VerityData, the stake purchase positions it as the 18th-biggest position in the Berkshire portfolio, standing behind Amazon and Constellation Brands. UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
The Hill
an hour ago
- The Hill
HHS will allow emergency use of animal drugs in New World screwworm fight
The Food and Drug Administration (FDA) became authorized on Tuesday to allow the use of animal drugs to treat or prevent infestations caused by the New World screwworm, a flesh-eating parasite that has recently disrupted the cattle industry. A declaration from the Department of Health and Human Services (HHS) will allow the FDA to issue emergency use authorizations for animal drugs to treat the insect. A spokesperson for HHS did not specify what medicines have been green-lit to combat the parasite. 'Our priority is to safeguard both animal health and the nation's food supply,' said FDA Commissioner Marty Makary. ' FDA is acting swiftly and responsibly to help ensure we have the necessary tools to prevent and control New World Screwworm, minimizing risks to agriculture and public health.' New World screwworms are a type of fly that lay their eggs in warm-blooded animals like cattle, horses, deer and even household pets like cats and dogs, according to the Department of Agriculture (USDA). Once the eggs hatch, the larvae can cause deadly damage to animals as they burrow into open wounds to feed on living tissue. In rare cases, the bugs have been known to attack humans, but HHS said in a statement that the current risk to human health in the U.S. 'remains very low.' But the potential future threat to animals and the country's food supply chain requires proactive action. USDA announced in May it would suspend all cattle, horse, and bison imports from Mexico after the bug was detected about 700 miles from the U.S. border in animals in Oaxaca and Veracruz. There are no FDA-approved drugs to treat the parasite in the U.S., but the agency can authorize the 'flexible, faster use' of certain animal drug products approved for other purposes or available in other countries under an emergency use authorization, according to a statement from HHS. 'Stopping this pest is a national security priority and we are linking arms across President Trump's cabinet to defend our borders and push back this threat,' said Agriculture Secretary Brooke L. Rollins.
